Does the media favor AGIO or PTGX?

In the previous week, Agios Pharmaceuticals had 5 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 19 mentions for Agios Pharmaceuticals and 14 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.28 beat Agios Pharmaceuticals' score of 0.31 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Protagonist Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AGIO or SYRE?

In the previous week, Agios Pharmaceuticals had 17 more articles in the media than Spyre Therapeutics. MarketBeat recorded 19 mentions for Agios Pharmaceuticals and 2 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.93 beat Agios Pharmaceuticals' score of 0.31 indicating that Spyre Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Spyre Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PRAX or AGIO?

In the previous week, Agios Pharmaceuticals had 15 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 19 mentions for Agios Pharmaceuticals and 4 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.17 beat Agios Pharmaceuticals' score of 0.31 indicating that Praxis Precision Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agios Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor QGEN or AGIO?

In the previous week, Agios Pharmaceuticals had 13 more articles in the media than Qiagen. MarketBeat recorded 19 mentions for Agios Pharmaceuticals and 6 mentions for Qiagen. Qiagen's average media sentiment score of 1.75 beat Agios Pharmaceuticals' score of 0.31 indicating that Qiagen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Agios Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Agios Pharmaceuticals (AGIO) Competitors

$36.36 +0.08 (+0.22%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$36.33 -0.03 (-0.10%)

As of 07/24/2026 07:34 PM Eastern

Compare

AGIO vs. PTGX, CRNX, SYRE, PRAX, and QGEN

Should you buy Agios Pharmaceuticals stock or one of its competitors? MarketBeat compares Agios Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Agios Pharmaceuticals include Protagonist Therapeutics (PTGX), Crinetics Pharmaceuticals (CRNX), Spyre Therapeutics (SYRE), Praxis Precision Medicines (PRAX), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry.

How does Agios Pharmaceuticals compare to Protagonist Therapeutics?

Agios Pharmaceuticals (NASDAQ:AGIO) and Protagonist Therapeutics (NASDAQ:PTGX) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Protagonist Therapeutics has a net margin of -154.88% compared to Agios Pharmaceuticals' net margin of -639.84%. Protagonist Therapeutics' return on equity of -17.76% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

Agios Pharmaceuticals currently has a consensus target price of $42.78, indicating a potential upside of 17.65%. Protagonist Therapeutics has a consensus target price of $123.00, indicating a potential downside of 9.63%. Given Agios Pharmaceuticals' higher probable upside, equities analysts plainly believe Agios Pharmaceuticals is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94

In the previous week, Agios Pharmaceuticals had 5 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 19 mentions for Agios Pharmaceuticals and 14 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.28 beat Agios Pharmaceuticals' score of 0.31 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protagonist Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protagonist Therapeutics has lower revenue, but higher earnings than Agios Pharmaceuticals. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03M	40.02	-$412.78M	-$7.25	N/A
Protagonist Therapeutics	$46.02M	190.21	-$130.15M	-$1.81	N/A

98.6% of Protagonist Therapeutics shares are owned by institutional investors. 5.4% of Agios Pharmaceuticals shares are owned by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Agios Pharmaceuticals has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market.

Summary

Protagonist Therapeutics beats Agios Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Agios Pharmaceuticals compare to Crinetics Pharmaceuticals?

Agios Pharmaceuticals (NASDAQ:AGIO) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

Agios Pharmaceuticals presently has a consensus price target of $42.78, indicating a potential upside of 17.65%. Crinetics Pharmaceuticals has a consensus price target of $78.27, indicating a potential downside of 6.52%. Given Agios Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Agios Pharmaceuticals is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Crinetics Pharmaceuticals	1 Sell rating(s)	10 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.29

98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 5.4% of Agios Pharmaceuticals shares are owned by company insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Agios Pharmaceuticals has a net margin of -639.84% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Agios Pharmaceuticals' return on equity of -34.11% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%

Agios Pharmaceuticals has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market.

In the previous week, Agios Pharmaceuticals had 10 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 19 mentions for Agios Pharmaceuticals and 9 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 0.94 beat Agios Pharmaceuticals' score of 0.31 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Crinetics Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Agios Pharmaceuticals has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03M	40.02	-$412.78M	-$7.25	N/A
Crinetics Pharmaceuticals	$18.07M	488.60	-$465.32M	-$5.13	N/A

Summary

Agios Pharmaceuticals beats Crinetics Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Agios Pharmaceuticals compare to Spyre Therapeutics?

Agios Pharmaceuticals (NASDAQ:AGIO) and Spyre Therapeutics (NASDAQ:SYRE) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Spyre Therapeutics has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -639.84%. Agios Pharmaceuticals' return on equity of -34.11% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%
Spyre Therapeutics	N/A	-42.88%	-27.76%

Agios Pharmaceuticals has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.02, indicating that its stock price is 202% more volatile than the broader market.

80.4% of Spyre Therapeutics shares are owned by institutional investors. 5.4% of Agios Pharmaceuticals shares are owned by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Agios Pharmaceuticals had 17 more articles in the media than Spyre Therapeutics. MarketBeat recorded 19 mentions for Agios Pharmaceuticals and 2 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.93 beat Agios Pharmaceuticals' score of 0.31 indicating that Spyre Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyre Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyre Therapeutics has lower revenue, but higher earnings than Agios Pharmaceuticals. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03M	40.02	-$412.78M	-$7.25	N/A
Spyre Therapeutics	N/A	N/A	-$155.20M	-$2.08	N/A

Agios Pharmaceuticals currently has a consensus target price of $42.78, suggesting a potential upside of 17.65%. Spyre Therapeutics has a consensus target price of $101.42, suggesting a potential downside of 0.70%. Given Agios Pharmaceuticals' higher probable upside, research analysts plainly believe Agios Pharmaceuticals is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

Summary

Spyre Therapeutics beats Agios Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Agios Pharmaceuticals compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Agios Pharmaceuticals (NASDAQ:AGIO) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

Praxis Precision Medicines has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -639.84%. Agios Pharmaceuticals' return on equity of -34.11% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-43.02%	-40.22%
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%

Praxis Precision Medicines has higher earnings, but lower revenue than Agios Pharmaceuticals. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	N/A	N/A	-$303.27M	-$13.37	N/A
Agios Pharmaceuticals	$54.03M	40.02	-$412.78M	-$7.25	N/A

Praxis Precision Medicines currently has a consensus price target of $563.50, indicating a potential upside of 73.22%. Agios Pharmaceuticals has a consensus price target of $42.78, indicating a potential upside of 17.65%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, research analysts clearly believe Praxis Precision Medicines is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	2.95
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

In the previous week, Agios Pharmaceuticals had 15 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 19 mentions for Agios Pharmaceuticals and 4 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.17 beat Agios Pharmaceuticals' score of 0.31 indicating that Praxis Precision Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agios Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Praxis Precision Medicines has a beta of 2.74, meaning that its stock price is 174% more volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

67.8% of Praxis Precision Medicines shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by company insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Praxis Precision Medicines beats Agios Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Agios Pharmaceuticals compare to Qiagen?

Qiagen (NYSE:QGEN) and Agios Pharmaceuticals (NASDAQ:AGIO) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

70.0% of Qiagen shares are held by institutional investors. 9.0% of Qiagen shares are held by insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Qiagen has a net margin of 19.16% compared to Agios Pharmaceuticals' net margin of -639.84%. Qiagen's return on equity of 14.40% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%

Qiagen has higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.10B	4.06	$424.88M	$1.91	21.66
Agios Pharmaceuticals	$54.03M	40.02	-$412.78M	-$7.25	N/A

Qiagen has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market.

In the previous week, Agios Pharmaceuticals had 13 more articles in the media than Qiagen. MarketBeat recorded 19 mentions for Agios Pharmaceuticals and 6 mentions for Qiagen. Qiagen's average media sentiment score of 1.75 beat Agios Pharmaceuticals' score of 0.31 indicating that Qiagen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Agios Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Qiagen currently has a consensus target price of $43.34, indicating a potential upside of 4.75%. Agios Pharmaceuticals has a consensus target price of $42.78, indicating a potential upside of 17.65%. Given Agios Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Agios Pharmaceuticals is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.36
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Summary

Qiagen beats Agios Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

Get Agios Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AGIO vs. The Competition

Export

Metric	Agios Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.16B	$3.67B	$6.88B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-5.02	21.11	27.00	23.71
Price / Sales	40.02	163.85	492.30	74.42
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	1.78	7.88	10.28	6.07
Net Income	-$412.78M	$23.81M	$3.60B	$331.99M
7 Day Performance	-8.20%	-3.82%	-1.29%	-0.61%
1 Month Performance	0.44%	-2.61%	-0.38%	-1.98%
1 Year Performance	-9.10%	32.79%	18.32%	13.67%

Agios Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AGIO Agios Pharmaceuticals	2.0956 of 5 stars	$36.36 +0.2%	$42.78 +17.7%	-8.3%	$2.16B	$54.03M	N/A	390	Trending News Upcoming Earnings Analyst Forecast Analyst Revision
PTGX Protagonist Therapeutics	1.5329 of 5 stars	$134.27 -4.7%	$123.00 -8.4%	+153.3%	$9.06B	$46.02M	N/A	120	News Coverage Positive News Analyst Upgrade
CRNX Crinetics Pharmaceuticals	2.2407 of 5 stars	$83.87 +0.0%	$78.27 -6.7%	+175.3%	$8.84B	$7.70M	N/A	210	Short Interest Decrease
SYRE Spyre Therapeutics	1.708 of 5 stars	$97.33 -2.9%	$101.42 +4.2%	+480.3%	$8.81B	$890K	N/A	73
PRAX Praxis Precision Medicines	4.0814 of 5 stars	$304.43 -3.2%	$563.50 +85.1%	+460.8%	$8.77B	$8.55M	N/A	110	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AGIO) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Agios Pharmaceuticals (AGIO) Competitors

AGIO vs. PTGX, CRNX, SYRE, PRAX, and QGEN

How does Agios Pharmaceuticals compare to Protagonist Therapeutics?

Summary

How does Agios Pharmaceuticals compare to Crinetics Pharmaceuticals?

Summary

How does Agios Pharmaceuticals compare to Spyre Therapeutics?

Summary

How does Agios Pharmaceuticals compare to Praxis Precision Medicines?

Summary

How does Agios Pharmaceuticals compare to Qiagen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGIO vs. The Competition

Agios Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Agios Pharmaceuticals (AGIO) Competitors

AGIO vs. PTGX, CRNX, SYRE, PRAX, and QGEN

How does Agios Pharmaceuticals compare to Protagonist Therapeutics?

Is AGIO or PTGX more profitable?

Do analysts rate AGIO or PTGX?

Does the media favor AGIO or PTGX?

Which has better valuation & earnings, AGIO or PTGX?

Do institutionals & insiders hold more shares of AGIO or PTGX?

Which has more risk and volatility, AGIO or PTGX?

Summary

How does Agios Pharmaceuticals compare to Crinetics Pharmaceuticals?

Do analysts rate AGIO or CRNX?

Do insiders & institutionals believe in AGIO or CRNX?

Is AGIO or CRNX more profitable?

Which has more risk and volatility, AGIO or CRNX?

Does the media favor AGIO or CRNX?

Which has stronger earnings & valuation, AGIO or CRNX?

Summary

How does Agios Pharmaceuticals compare to Spyre Therapeutics?

Is AGIO or SYRE more profitable?

Which has more risk and volatility, AGIO or SYRE?

Do insiders & institutionals believe in AGIO or SYRE?

Does the media favor AGIO or SYRE?

Which has higher earnings & valuation, AGIO or SYRE?

Do analysts recommend AGIO or SYRE?

Summary

How does Agios Pharmaceuticals compare to Praxis Precision Medicines?

Is PRAX or AGIO more profitable?

Which has preferable valuation & earnings, PRAX or AGIO?

Do analysts recommend PRAX or AGIO?

Does the media favor PRAX or AGIO?

Which has more volatility & risk, PRAX or AGIO?

Do insiders & institutionals have more ownership in PRAX or AGIO?

Summary

How does Agios Pharmaceuticals compare to Qiagen?

Do insiders & institutionals have more ownership in QGEN or AGIO?

Is QGEN or AGIO more profitable?

Which has preferable valuation & earnings, QGEN or AGIO?

Which has more risk and volatility, QGEN or AGIO?

Does the media favor QGEN or AGIO?

Do analysts recommend QGEN or AGIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGIO vs. The Competition

Agios Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools